Literature DB >> 18571236

Evaluation of interleukin-2 treatment for prevention of intramammary infections in cows after calving.

Alfonso Zecconi1, Renata Piccinini, Silvia Fiorina, Luca Cabrini, Valentina Daprà, Massimo Amadori.   

Abstract

A low-dose treatment based on interleukin-2 (IL-2) was investigated for preventing mastitis in dairy cows. The treatment consisted of a single dose of IL-2 injected into the skin region drained by the supramammary lymph node 3-5 days after calving. The study included 45 cows (23 treated and 22 controls) from three commercial dairy herds. The results showed that the treatment had no side effects. The treatment with IL-2 induced the significant increase of several milk markers related to leukocyte and epithelial cell functions, i.e. SCC (somatic cell counts), serum amyloid A (SAA), lactoferrin and NAGase. The increased concentration of milk markers suggested also an activity of IL-2 on epithelial cells, resulting in a higher resistance to invading pathogens. Indeed, the increased efficiency of cells in the udder is supported by the higher frequency of healthy quarters observed in the treated group until day 17-19 after calving, in comparison with the control one.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571236     DOI: 10.1016/j.cimid.2008.05.001

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  2 in total

Review 1.  Trends in recombinant protein use in animal production.

Authors:  Laia Gifre; Anna Arís; Àlex Bach; Elena Garcia-Fruitós
Journal:  Microb Cell Fact       Date:  2017-03-04       Impact factor: 5.328

Review 2.  Advances in therapeutic and managemental approaches of bovine mastitis: a comprehensive review.

Authors:  Khan Sharun; Kuldeep Dhama; Ruchi Tiwari; Mudasir Bashir Gugjoo; Mohd Iqbal Yatoo; Shailesh Kumar Patel; Mamta Pathak; Kumaragurubaran Karthik; Sandip Kumar Khurana; Rahul Singh; Bhavani Puvvala; Rajendra Singh; Karam Pal Singh; Wanpen Chaicumpa
Journal:  Vet Q       Date:  2021-12       Impact factor: 3.320

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.